FDA Proposes Antihypertensive Class Indication For Reducing CV Events
This article was originally published in The Pink Sheet Daily
Executive Summary
Adding an indication for reducing cardiovascular adverse event risk is one option FDA will have its Cardiovascular & Renal Drugs Advisory Committee consider for antihypertensive class labeling June 15. Other class labeling options offered in FDA briefing document would amend the clinical trials section.
You may also be interested in...
Pfizer To Present ALLHAT Analysis At Advisory Committee On Antihypertensive Labeling
The company will present a non-inferiority analysis suggesting Norvasc (amlodipine) is similar to the diuretic chlorthalidone in preventing hypertension outcomes during a June 15 meeting of FDA's Cardiovascular & Renal Drugs Advisory Committee, the agency says.
Pfizer To Present ALLHAT Analysis At Advisory Committee On Antihypertensive Labeling
The company will present a non-inferiority analysis suggesting Norvasc (amlodipine) is similar to the diuretic chlorthalidone in preventing hypertension outcomes during a June 15 meeting of FDA's Cardiovascular & Renal Drugs Advisory Committee, the agency says.
NitroMed BiDil Heart Failure Indication For African Americans To Be Reviewed By Cmte.
FDA's Cardiovascular & Renal Drugs Advisory Committee will meet June 16 to consider the resubmitted BiDil NDA. Drug could be first approval specifically for African Americans. Committee will also meet June 15 to discuss antihypertensive class labeling.